Technology Adoption Program (TAP) program success demonstrates the ability of Cellares’ IDMO Smart Factory to automate, lower costs and scale out manufacturing for Cabaletta Bio’s clinical-stage CAR T ...
Cellares, in collaboration with Mitsui Fudosan, a Japanese real estate developer, established Japan’s first next-gen commercial production site for CAR-T cell therapies. The facility is under ...
New solutions include customized reagents that scale from bench to clinical trials, industrialized lentiviral vector ...
The AMT designation gives Cellares’ clients using the Cell Shuttle priority review with the FDA leading to accelerated regulatory filings SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the ...
Cause-Specific Mortality in a Cohort of 1,435 Patients With Hodgkin Lymphoma Treated Between 1985 and 2014: A Nationwide Chilean Cohort Study Healthy volunteers were recruited and underwent ...
A detailed analysis of T-cell redirecting therapies in oncology, comparing the mechanisms of bispecific antibodies and CAR T ...
Cell and gene therapy (CGT) has evolved from a niche research pursuit into a central force in biopharmaceutical innovation. By engineering living cells and genetic material to repair or replace faulty ...
Ori Biotech has lassoed a significant milestone for its space- and cost-efficient cell and gene therapy manufacturing platform. The FDA has granted the company’s IRO platform an Advanced Manufacturing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results